Bank of New York Mellon Corp Purchases New Holdings in CeriBell (NASDAQ:CBLL)

Bank of New York Mellon Corp acquired a new position in shares of CeriBell (NASDAQ:CBLL) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 24,274 shares of the company’s stock, valued at approximately $628,000. Bank of New York Mellon Corp owned 0.07% of CeriBell at the end of the most recent reporting period.

Separately, Rhumbline Advisers bought a new position in shares of CeriBell in the fourth quarter worth $320,000.

CeriBell Price Performance

Shares of NASDAQ CBLL opened at $19.57 on Thursday. CeriBell has a 12 month low of $18.69 and a 12 month high of $32.75. The business’s 50-day simple moving average is $22.37.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. On average, sell-side analysts predict that CeriBell will post -2.46 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on CBLL. Canaccord Genuity Group reiterated a “buy” rating and set a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. TD Cowen increased their price target on shares of CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $32.60.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.